EUVIMEDEUVIMED entdecken
Crossref

Efficacy of adjuvant amikacin combined with oral levofloxacin as prophylaxis for transrectal prostate biopsy in patients harboring fluoroquinolone-resistant Escherichia coli in rectal flora

Yoshitsugu Nasu, Masanori Hanamoto, Ryota Fujisawa, Daisuke Tanaka, Noriko Kosaka

International Urology and Nephrology · 2025

DOI: 10.1007/s11255-025-04569-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Yoshitsugu Nasu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Okayama Rosai Hospital, 1-10-25 Chikkou-Midorimachi, South-Ward, Okayama, 7028055, Japan. khscuro@hotmail.com. Hauptthemen laut MEDLINE: Levofloxacin, Antibiotic Prophylaxis, Escherichia coli, Amikacin. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Fluoroquinolones (FQs) are commonly used as antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy (TRPB). The presence of FQ-resistant E. coli (QREC) in the rectal flora is thought to be a risk factor for febrile complications following the TRPB, and culture-based antimicrobial selection is recommended as prophylaxis for patients with QREC. Amikacin (AMK) is a promising prophylactic agent because of its potent antimicrobial activity against QREC and excellent permeability of the prostate tissue. We evaluated the efficacy of adjuvant AMK in combination with oral levofloxacin (LVFX) as an antibiotic prophylaxis for TRPB. METHODS: Between October 2016 and September 2024, 531 patients with E. coli isolated from rectal swab cultures were enrolled. Patients with diabetes, urinary tract infections, or those on immunosuppressive agents were excluded. Rectal swabs were cultured prior to TRPB. Isolated E. coli was determined as QREC when their minimum inhibitory concentration (MIC) of LVFX was 4 μg/mL or above. As antimicrobial prophylaxis for all patients, a single oral 500 mg of LVFX was administered 2 h before TRPB. For patients with QREC, AMK 400 mg was administered intravenously before the TRPB. The patients were followed up for 30 days after the TRPB and febrile infective complications were recorded. RESULTS: Fifty-nine QREC carriers (11.1%) were identified. All QREC were sensitive to AMK. Eleven (2.1%) patients experienced febrile complications after TRPB. Four of them were QREC carriers and the others were non-QREC carriers. The incidence of febrile complications following TRPB among QREC carriers was higher than that among non-QREC carriers (6.8%, 4/59 vs 1.5%, 7/472; p = 0.025, Fisher's exact test). CONCLUSIONS: Infection control with an AMK adjuvant to oral LVFX in QREC carriers had limitations, although all QREC were sensitive to AMK. We concluded that culture-based antimicrobial prophylaxis has limitations in the complete prevention of febrile complications following TRPB. While escalation or further augmentation of prophylactic agents will reduce febrile complications in the short term, it will accelerate the increase in resistant bacteria in the long term and violate the principles of good antibiotic stewardship. For resistant strain carriers, switching to transperineal prostate biopsy should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevofloxacinAntibiotic ProphylaxisEscherichia coliAmikacinRectumAnti-Bacterial AgentsProstateEscherichia coli InfectionsHumansMaleAgedAdministration, OralMiddle AgedDrug Therapy, CombinationDrug Resistance, BacterialImage-Guided BiopsyFluoroquinolonesTreatment OutcomeChemotherapy, Adjuvant

Stichwörter der Autor:innen

AmikacinAntibiotic prophylaxisFluoroquinolone-resistant Escherichia coliLevofloxacinRectal swab cultureTransrectal prostate biopsy

Substanzen

LevofloxacinAmikacinAnti-Bacterial AgentsFluoroquinolones

Autor:innen und Institutionen

  • Department of Urology, Okayama Rosai Hospital, 1-10-25 Chikkou-Midorimachi, South-Ward, Okayama, 7028055, Japan. khscuro@hotmail.com.
  • Department of Urology, Okayama Rosai Hospital, 1-10-25 Chikkou-Midorimachi, South-Ward, Okayama, 7028055, Japan.

Zitieren

APA

Nasu, Y., Hanamoto, M., Fujisawa, R., Tanaka, D., & Kosaka, N. (2025). Efficacy of adjuvant amikacin combined with oral levofloxacin as prophylaxis for transrectal prostate biopsy in patients harboring fluoroquinolone-resistant Escherichia coli in rectal flora. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04569-0

Vancouver

Nasu Y, Hanamoto M, Fujisawa R, Tanaka D, Kosaka N. Efficacy of adjuvant amikacin combined with oral levofloxacin as prophylaxis for transrectal prostate biopsy in patients harboring fluoroquinolone-resistant Escherichia coli in rectal flora. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04569-0

BibTeX
@article{Nasu2025,
  author = {Nasu, Yoshitsugu and Hanamoto, Masanori and Fujisawa, Ryota and Tanaka, Daisuke and Kosaka, Noriko},
  title = {Efficacy of adjuvant amikacin combined with oral levofloxacin as prophylaxis for transrectal prostate biopsy in patients harboring fluoroquinolone-resistant Escherichia coli in rectal flora},
  journal = {International Urology and Nephrology},
  year = {2025},
  doi = {10.1007/s11255-025-04569-0}
}
Kostenlos starten →